Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Kondo M, Dalai SC, Venkatasubrahmanyam S, Eisenberg N, Robinson BD, Westblade LF, et al. Diagnosis and Genotyping of Endocarditis in a Patient with Prosthetic Pulmonary Valve Replacement Using Next-Generation Sequencing of Plasma Microbial Cell-Free DNA. Open Forum Infect Dis. 2019;6(6):ofz242.

Alvarez MJ, Yan P, Alpaugh ML, Bowden M, Sicinska E, Zhou CW, et al. Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines'. Nat Genet. 2019;51(10):1427-1428.

Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, et al. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019;25(22):6839-6851.

Lee Y-, Uchida H, Smith H, Ito A, Sanchez T. The isolation and molecular characterization of cerebral microvessels. Nat Protoc. 2019;14(11):3059-3081.

Vlismas PP, Heymann JJ, Marboe CC, Jorde UP, Sims DB. Quadravalvular Noninfectious Endocarditis. JACC Case Rep. 2019;1(3):350-354.

Magro CM, Olson LC, Momtahen S. Post-thymic CD4 positive cytotoxic T cell infiltrates of the skin: A clinical and histomorphologic spectrum of the unique CD4 positive T cell of immunosenescence. Ann Diagn Pathol. 2019;38:99-105.

Maura F, Agnelli L, Leongamornlert D, Bolli N, Chan WC, Dodero A, et al. Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma. Am J Hematol. 2019;94(6):628-634.

Hamid AA, Gray KP, Shaw G, Macconaill LE, Evan C, Bernard B, et al. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. Eur Urol. 2019;76(1):89-97.

Schwartz Z, Magro C, Nuovo G. The molecular-based differentiation of Heck's disease from its mimics including oral condyloma and white sponge nevus. Ann Diagn Pathol. 2019;43:151402.

Bartlett NL, Wilson WH, Jung S-, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790-1799.